Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Liver cirrhosis (LC) represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and formation of regenerative nodules. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems. The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. Particularly, autologous bone marrow-derived mesenchymal stem cell (BM-MSC) has been demonstrated to decrease MELD score and increase serum albumin in the patients with decompensated liver cirrhosis. Therefore, the investigators propose a hypothesis that umbilical cord-derived MSCs (UC-MSC) can also improve the disease conditions of LC patients, particularly reducing the decompensated conditions in these patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing 302 Hospital

Criteria

Inclusion Criteria:

1. Liver cirrhosis

2. Negative pregnancy test (female patients in fertile age)

3. written consent

Exclusion Criteria:

1. Hepatocellular carcinoma or other malignancies

2. Pregnancy

3. sepsis

4. Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)

5. Cardiac, renal or respiratory failure

6. Active thrombosis of the portal or hepatic veins